Please assess the completion status of the following clinical trial:

Trial Title: Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA:~  1. Adults greater than or equal to 18 years of age.~ 2. Patients will provide informed consent.~ 3. Biopsy proven FSGS.~ 4. Glomerular filtration rate of at least 25 and no more than 80 ml/minute as assessed by the 4 variable Modification of diet in renal disease GFR equation.~ 5. At least 6 months of renal function data must be available prior to the patient's receiving pirfenidone, and renal function must show a rate of decline of greater than or equal to 0.4 ml/min/month during this baseline period.~ 6. Patients must have received no glucocorticoids, cyclophosphamide, mycophenolate or other immunosuppressive drugs for at least 2 months prior to the study period.~ 7. Patients must have received no cyclosporin for at least 6 months prior to the study period.~ 8. Patients must have been taking an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) at a stable dose for at least 6 months, unless intolerant of both classes of medication.~ 9. Patients who are HIV seropositive will receive standard care for HIV disease (patients receiving immune-modulating therapy will be excluded).~ 10. Women with child-bearing potential must maintain an effective birth control regimen (oral contraceptive, intrauterine device, barrier plus spermicide).~ 11. Men will be advised that although Ames testing has been negative for any evidence of mutagenicity, they should consider use of contraceptives during the study period as well.~EXCLUSION CRITERIA:~1. Inability to give informed consent or cooperate with study.~2. Known intolerance to pirfenidone.~3. Evidence of FSGS associated with an additional primary or secondary glomerular disease (e.g. diabetes, membranous nephropathy, IgA nephropathy).~4. Recent (within 6 months) history of myocardial infarction.~5. History of peptic ulcer within 6 months.~6. History of cerebrovascular disease manifested by transient ischemic attack or cerebrovascular accident within 6 months.~7. Pregnancy, breast feeding or inadequate birth control.~8. History of photosensitivity dermatitis.~9. Concurrent drug treatment with gemfibrozil, cyclosporin or erythromycin, potassium-sparing diuretics and other drugs which may potentiate hyperkalemia, or concurrent immunosuppresive medications.~10. Requirement for NSAID therapy.~11. Requirement for interleukin-2 therapy or other immune-modulating medication.~12. Existence of any other condition which would complicate the implementation or interpretation of the study.~13. Renal transplant.~14. Evidence of significant hepatic disease, as indicated by serum transaminases greater than 3 times upper limit of normal, protime greater than 2 seconds prolonged.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete